Alzamend Neuro, Inc. financial data

Symbol
ALZN on Nasdaq
Location
3500 Lenox Rd. Ne, Suite 1500, Atlanta, GA
Fiscal year end
April 30
Latest financial report
10-Q - Q2 2025 - Sep 10, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 449 % -64.7%
Debt-to-equity 21.8 %
Return On Equity -181 % -144%
Return On Assets -124 % +82.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3.14M shares -19.3%
Common Stock, Shares, Outstanding 3.14M shares +265%
Entity Public Float 8.2M USD +22.4%
Common Stock, Value, Issued 314 USD +265%
Weighted Average Number of Shares Outstanding, Basic 2.11M shares +2369%
Weighted Average Number of Shares Outstanding, Diluted 2.11M shares +2369%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 2.95M USD -31.3%
General and Administrative Expense 3.29M USD +6.72%
Costs and Expenses 14.9M USD +20.7%
Operating Income (Loss) -6.23M USD +15.5%
Nonoperating Income (Expense) -8.51K USD +58%
Net Income (Loss) Attributable to Parent -6.24M USD +15.6%
Earnings Per Share, Basic -1 USD/shares +99.1%
Earnings Per Share, Diluted -1 USD/shares +99.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 5.62M USD +371%
Assets, Current 5.93M USD +319%
Property, Plant and Equipment, Net 398K USD +56.9%
Assets 6.33M USD +279%
Accounts Payable, Current 726K USD -81%
Liabilities, Current 3.83M USD +44.8%
Liabilities 983K USD -65.9%
Retained Earnings (Accumulated Deficit) -61.2M USD -11.4%
Stockholders' Equity Attributable to Parent 5.34M USD
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 3.97M USD
Liabilities and Equity 6.33M USD +279%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.36M USD -124%
Net Cash Provided by (Used in) Financing Activities 4.04M USD +105%
Net Cash Provided by (Used in) Investing Activities -90K USD +38.9%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 3.14M shares +265%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 5.62M USD +371%
Deferred Tax Assets, Valuation Allowance 15.2M USD -3.29%
Deferred Tax Assets, Gross 15.3M USD -3.34%
Depreciation 27.7K USD +118%
Deferred Tax Assets, Operating Loss Carryforwards 10.6M USD -2.51%
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 66.6M USD +23.8%
Share-based Payment Arrangement, Expense 81.3K USD -56.5%
Interest Expense 8.51K USD -58%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%